Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.

about

The impact of immunohistochemistry on the classification of lung tumors.

P2860

Q38822314-255356C2-DB05-4E46-AF09-292CE6634B62

P2860

Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.

Item

http://www.wikidata.org/entity/Q45276482

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Does immunohistochemistry affe ...... tage III-IV consecutive cases.

@en

Does immunohistochemistry affe ...... tage III-IV consecutive cases.

@nl

type

Item

label

Does immunohistochemistry affe ...... tage III-IV consecutive cases.

@en

Does immunohistochemistry affe ...... tage III-IV consecutive cases.

@nl

prefLabel

Does immunohistochemistry affe ...... tage III-IV consecutive cases.

@en

Does immunohistochemistry affe ...... tage III-IV consecutive cases.

@nl

P1476

Does immunohistochemistry affe ...... stage III-IV consecutive cases

@en

P2093

Eva Regina Haspinger

http://www.w3.org/2001/XMLSchema#string

Giorgia Leone

http://www.w3.org/2001/XMLSchema#string

Giuseppe Pelosi

http://www.w3.org/2001/XMLSchema#string

Manuela Bimbatti

http://www.w3.org/2001/XMLSchema#string

Silvana Pilotti

http://www.w3.org/2001/XMLSchema#string

P2860

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.

New driver mutations in non-small-cell lung cancer.

A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.

Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer.

Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples.

Large cell carcinoma of the lung: an endangered species?

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

Impact of histopathological diagnosis with ancillary immunohistochemical studies on lung cancer subtypes incidence and survival: a population-based study.

Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation

P304

136-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1066896913511527

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24326823

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.

about

P2860

P2860

Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921